Pay in 4 interest-free payments of $6.37 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Recognizing these helps ensure appropriate responses
2026 Mar 11;148(9):10225-10240
For a non-competing adult working with a physician willing to supervise off-label use, the risk-to-benefit profile may be acceptable given the volume of animal evidence, but anyone expecting human RCT-level proof is not yet there
It is important to note that exact dosing schedules varied between trial cohorts and protocols
US$ 27.88
US$ 28.39
US$ 23.68
US$ 24.95
US$ 28.36
US$ 25.43
US$ 22.63
